10.50
-0.14 (-1.32%)
| Penutupan Terdahulu | 10.64 |
| Buka | 10.50 |
| Jumlah Dagangan | 1,571,165 |
| Purata Dagangan (3B) | 2,718,011 |
| Modal Pasaran | 733,048,000 |
| Harga / Jualan (P/S) | 7.62 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 6 Aug 2025 - 11 Aug 2025 |
| Margin Operasi (TTM) | -276.53% |
| EPS Cair (TTM) | -5.18 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 1,391.60% |
| Nisbah Semasa (MRQ) | 3.58 |
| Aliran Tunai Operasi (OCF TTM) | -282.68 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -201.84 M |
| Pulangan Atas Aset (ROA TTM) | -55.01% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menurun |
| Biotechnology (Global) | Bercampur | Menurun | |
| Stok | Phathom Pharmaceuticals, Inc. | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 1.5 |
| Osilator Teknikal | 2.0 |
| Purata | 0.25 |
|
Phathom Pharmaceuticals Inc operates as a clinical-stage biopharmaceutical company. The firm is focused on developing and commercializing novel treatments for gastrointestinal, or GI, diseases. Its product comprises vonoprazan, an oral small-molecule potassium competitive acid blocker medicine that blocks acid secretion in the stomach. Vonoprazan shows rapid, potent, and durable anti-secretory effects and has demonstrated clinical benefits in the treatment of gastroesophageal reflux disease, and in combination with antibiotics for the treatment of Helicobacter pylori infection. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Value |
| % Dimiliki oleh Orang Dalam | 4.28% |
| % Dimiliki oleh Institusi | 84.72% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Catalys Pacific, Llc | 31 Mar 2025 | 1,167,114 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 28.00 (Needham, 166.67%) | Beli |
| Median | 17.00 (61.91%) | |
| Rendah | 5.00 (Goldman Sachs, -52.38%) | Pegang |
| Purata | 16.40 (56.19%) | |
| Jumlah | 4 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 6.42 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Craig-Hallum | 09 Jun 2025 | 17.00 (61.90%) | Beli | 8.83 |
| HC Wainwright & Co. | 09 Jun 2025 | 20.00 (90.48%) | Beli | 8.83 |
| 02 May 2025 | 20.00 (90.48%) | Beli | 2.76 | |
| Needham | 06 Jun 2025 | 28.00 (166.67%) | Beli | 8.92 |
| 21 Apr 2025 | 28.00 (166.67%) | Beli | 3.90 | |
| Goldman Sachs | 02 May 2025 | 5.00 (-52.38%) | Pegang | 2.76 |
| Guggenheim | 02 May 2025 | 12.00 (14.29%) | Beli | 2.76 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |